Free shipping on all orders over $ 500

Cilengitide

Cat. No. M2042

All AbMole products are for research use only, cannot be used for human consumption.

Cilengitide Structure
Synonym:

EMD 121974, NSC 707544

Size Price Availability Quantity
2mg USD 50  USD50 In stock
5mg USD 80  USD80 In stock
10mg USD 130  USD130 In stock
25mg USD 260  USD260 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Cilengitide is a molecule designed and synthesized at the Technical University Munich in collaboration with Merck KGaA in Darmstadt. Cilengitide binds to the activities of the αvβ3 and αvβ5 integrins, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis. Cilengitide (EMD 121974) could increase systemic RIT efficacy of therapy in a human breast cancer tumor model having mutant p53 and expressing bcl-2. Cilengitide is currently in clinical phase III for treatment of glioblastomas and in phase II for several other tumors.

Product Citations
Chemical Information
Molecular Weight 588.66
Formula C27H40N8O7
CAS Number 188968-51-6
Solubility (25°C) DMSO: ≥ 45 mg/mL
Storage -20°C, dry, sealed
References

[1] Nabors LB, et al. Cancer. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).

[2] Burke PA, et al. Cancer Res. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.

Related Integrin Products
αvβ1 integrin-IN-1

αvβ1 integrin-IN-1 is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM. αvβ1 integrin-IN-1 has antifibrotic effects.

MORF-627

MORF-627 is a selective, orally active inhibitor for integrin αvβ6 with an IC50 of 9.2 nM (measuring by human serum ligand binding assay). MORF-627 inhibits αvβ6-mediated TGF-β1 activation with an IC50 of 2.63 nM, inhibits SMAD2/3 phosphorylation with an IC50 of 8.3 nM.

Volociximab

Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs).

GSK 3008348 hydrochloride 

GSK 3008348 hydrochloride is a small molecule integrin αvβ6 antagonist.

HSDVHK-NH2

HSDVHK-NH2 is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC50 of 1.74 pg/mL (2.414 pM).

  Catalog
Abmole Inhibitor Catalog




Keywords: Cilengitide, EMD 121974, NSC 707544 supplier, Integrin, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.